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Background: Overexpression of heterogeneous nuclear ribonucleoprotein K (hnRNP K), a DNA/RNA binding
protein, is associated with metastasis in nasopharyngeal carcinoma (NPC). However, the mechanisms underlying
hnRNP K-mediated metastasis is unclear. The aim of the present study was to determine the role of matrix
metalloproteinase (MMP) in hnRNP K-mediated metastasis in NPC.
Methods: We studied hnRNP K-regulated MMPs by analyzing the expression profiles of MMP family genes in NPC
tissues and hnRNP K-knockdown NPC cells using Affymetrix microarray analysis and quantitative RT-PCR. The association
of hnRNP K and MMP12 expression in 82 clinically proven NPC cases was determined by immunohistochemical analysis.
The hnRNP K-mediated MMP12 regulation was determined by zymography and Western blot, as well as by promoter,
DNA pull-down and chromatin immunoprecipitation (ChIP) assays. The functional role of MMP12 in cell migration and
invasion was demonstrated by MMP12-knockdown and the treatment of MMP12-specific inhibitor, PF-356231.
Results: MMP12 was overexpressed in NPC tissues, and this high level of expression was significantly correlated with
high-level expression of hnRNP K (P = 0.026). The levels of mRNA, protein and enzyme activity of MMP12 were reduced
in hnRNP K-knockdown NPC cells. HnRNP K interacting with the region spanning −42 to −33 bp of the transcription
start site triggered transcriptional activation of the MMP12 promoter. Furthermore, inhibiting MMP12 by MMP12
knockdown and MMP12-specific inhibitor, PF-356231, significantly reduced the migration and invasion of NPC cells.
Conclusions: Overexpression of MMP12 was significantly correlated with hnRNP K in NPC tissues. HnRNP K can induce
MMP12 expression and enzyme activity through activating MMP12 promoter, which promotes cell migration and
invasion in NPC cells. In vitro experiments suggest that NPC metastasis with high MMP12 expression may be treated
with PF-356231. HnRNP K and MMP12 may be potential therapeutic markers for NPC, but additional validation studies
are warranted.
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Heterogeneous nuclear ribonucleoprotein K (hnRNP K),
a member of the hnRNP family, is aberrantly increased
in multiple types of cancer [1-5], including nasopharyn-
geal carcinoma (NPC) [5]. HnRNP K is a nucleocyto-
plasmic shuttling protein that is primarily located in the
nucleus, where it is involved in transcriptional regulation
[6]. It may act as either a transactivator [7-9] or transre-
pressor [10], depending on the interacting factors in-
volved. In terms of the post-transcriptional regulation of
hnRNP K, its cytoplasmic accumulation is governed by
ERK-mediated phosphorylation at serines-284 and −353
[11,12]. The tumorigenic potential of hnRNP K is medi-
ated by various tumor-associated genes, such as FLIP [7],
TP [11], eIF4E [13] and c-Myc [14]. High-level hnRNP K
expression has been correlated with decreased metastasis-
free survival in NPC patients and may promote metastasis
of NPC cells in part by inducing downstream metastasis-
related genes [5,7]. To investigate the regulatory mechan-
ism underlying hnRNP K-mediated metastasis, microarray
analysis were performed in the hnRNP K-knockdown or
in control NPC cells. Our preliminary data indicated that
matrix metalloproteinase 12 (MMP12) was one of the
hnRNP K-activated downstream targets.
The MMP family has 23 members that differ in their
substrate specificities toward various components of the
extracellular matrix (ECM). Structurally, the MMPs gen-
erally include a highly conserved propeptide domain, a
zinc-binding catalytic domain, and a hemopexin-like do-
main; a catalytic zinc ion is required for their proteolytic
activity [15]. MMPs are involved in many phases of can-
cer progression, including tumor invasion, metastasis,
and angiogenesis [16,17]. Previously, it has been re-
ported that induction of MMP1 [18], MMP2 [19,20] and
MMP9 [21] expression were detected and correlated
with poor prognosis in NPC due to the invasive and
metastatic role of MMPs. This increase in MMPs ex-
pression is mainly caused by EBV latent membrane pro-
tein 1 (LMP1) [22], LMP2A [23] and Zta [24]. To data,
however, no study has specifically examined the expres-
sion of MMP12 in NPC. MMP12, also known as macro-
phage metalloelastase is overexpressed in many cancer
types, and high-level MMP12 expression has been asso-
ciated with poor prognosis and increased risk of metas-
tasis in cancer patients [25-28]. In malignant cells, the
tumor microenvironment, which contains various in-
flammatory mediators (e.g., TNFα and GM-CSF), was
found to positively regulate MMP12 expression through
the activation of NF-κB and AP-1 [29,30]. MMP12 has
also been shown to be involved in cell invasion [31,32],
proliferation [33] and angiogenesis [34].
NPC is more prominent in Southeastern China and
Taiwan than in Western countries. Epidemiological stud-
ies have indicated that infection with Epstein-Barr virus(EBV), dietary habits, and genetic susceptibility might be
critical cofactors in the development of NPC [35,36].
Radiotherapy is traditionally the first choice for treating
primary NPC. Under the current combined treatments
with both radio- and chemotherapy regimens, the survival
rates among NPC patients are ~92% at 1 year and ~50%
at 5 years, with 20-25% of patients eventually developing
distant metastases [37].
We previously reported that hnRNP K can be a prog-
nostic biomarker for NPC, and regulates TP and FLIP
post-transcriptionally and transcriptionally, respectively
[7,11]. In the present study, we show that hnRNP K can
regulate MMP12 expression transcriptionally, and pro-
motes the migration and invasion of NPC cells. MMP12
inhibitor PF-356231 prevents NPC cell migration and in-
vasion in vitro. Clinically, elevated expression of MMP12
was significantly correlated with high-level expression of
hnRNP K in NPC biopsy tissues.
Methods
Cell culture
The NPC-derived cell line, TW02 [38], derived from a
keratinizing squamous cell carcinoma [World Health
Organization (WHO) type I], was provided by Dr. C. T.
Lin (National Taiwan University, Taiwan). The NPC-
derived cell line, HK1 [39], derived from a keratinizing
squamous cell carcinoma (WHO type I), was provided
by Dr. S. W. Tsao (Hong Kong University, SAR, China).
NPC-TW02 and NPC-HK1 cells were culture in Dulbec-
co’s modified Eagle’s medium (DMEM, Gibco BRL,
Rockville, MD) and RPMI1640 (Gibco BRL), respect-
ively. All NPC cell lines were supplemented with 10%
fetal calf serum (FCS), 100 U/ml penicillin, and 100 μg/ml
streptomycin at 37°C under 5% CO2.
Affymetrix microarray analysis
RNA samples from hnRNP K-knockdown NPC-TW02
cells, control NPC-TW02 cells, nine individual NPC tis-
sues and one pool of the corresponding adjacent non-
tumor tissues, were isolated using the TRIzol reagent
(Invitrogen, Carlsbad, CA). The biotinylated oligonucleo-
tide was hybridized to the Human Genome U133 Plus 2.0
Array (Affymetrix, Santa Clara, CA) by the National Yang-
Ming University Genomics Center (Taiwan), following the
manufacturer’s instructions. Microarray data were ana-
lyzed using the GeneSpring software version GX 7.31 (Sili-
con Genetics, Redwood, CA). The ratio of the average
hybridization intensity between hnRNP K-knockdown/
control NPC-TW02 cells or NPC tumor/normal tissue
was taken as the relative gene expression level.
Quantitative RT-PCR
RNA samples from NPC-TW02, and -HK1 cells and NPC
tissues were isolated using the TRIzol reagent (Invitrogen).
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oligo(dT)20 primers (Invitrogen) and Moloney Murine
Leukemia Virus (M-MLV) Reverse Transcriptase (Invitro-
gen) according to the manufacturer’s instructions. The
primers used to amplify the cDNA corresponding to
MMP1, MMP12, MMP13, MMP28 and GAPDH are pre-
sented in Additional file 1: Table S1. Quantitative RT-PCR
was performed on a Light-Cycler (Roche Diagnostics,
Mannheim, Germany), using the FastStart DNA Master
SYBR Green I reagent (Roche Diagnostics). The gene ex-
pression results were normalized with regard to the ex-
pression of the GADPH. For mRNA half-life assessment,
actinomycin D (5 μg/ml) was added 48 hours after cells
were transfected with control or hnRNP K-targeting
siRNA, and RNA was prepared at the indicated times.
RNA interference
SMART pool reagents, including four RNA duplexes tar-
geting hnRNP K and MMP-12 were purchased from
Dharmacon (Lafayette, CO), and the negative control
siRNA was synthesized by Eurogentec S.A. (Liege, Belgium).
The target sequences of the siRNA were as follows: hnRNP
K, 5'-UAAAC GCCCU GCAGA AGAUU U-3', 5'-GGUCG
UGGCU CAUAU GGUGU U-3', 5'-UGACA GAGUU
GUUCU UAUUU U-3' and 5'-GCAAG AAUAU UAAGG
CUCUU U-3'. NPC cells were transfected with double-
stranded (ds) RNA duplexes (50 nmol/L) using the
Lipofectamine 2000 reagent (Invitrogen).
Patients and clinical characteristics
The retrospective cohort comprised 82 NPC patients
who had been admitted to Chang Gung Memorial Hos-
pital (Lin-Kou, Taiwan) from 1990 to 1998. Clinical stage
was defined according to the 2002 cancer staging system
revised by the American Joint Committee on Cancer.
The study population included 17 stage-I-II and 65
stage-III-IV patients comprising 61 men and 21 women
ranging from 22 to 78 years of age (median age 44).
Histological typing was done according to the WHO
classification criteria, as previously described [40]. This
study was reviewed and approved by the institutional re-
view board and ethics committee of Chang Gung Me-
morial Hospital. Informed consent was obtained from all
patients.
Immunohistochemical staining
Immunohistochemical analyses were performed as de-
scribed previously [5,7,37,40], using an automatic IHC-
staining device (Bond-max Automated Immunostainer;
Vision Biosystems, Melbourne, Australia), according to
the manufacturer’s instructions. Tissue sections were re-
trieved using Bond Epitope Retrieval Solution 1 (Vision
BioSystems) and stained with antibodies against hnRNP
K (mouse monoclonal antibody, 1:300 dilution; SantaCruz Biotechnology, Santa Cruz, CA, USA) and MMP-
12 (goat polyclonal antibody, 1:10 dilution; Santa Cruz
Biotechnology). A polymer detection system (Bond Poly-
mer Refine; Vision BioSystems) was used to reduce non-
specific staining. Tissue sections were treated with liquid
DAB reagent; 3’-diaminobenzidine tetrahydrochloride
was used as the chromogen, and hematoxylin was used
as the counterstaining reagent. For analysis of total
hnRNP K expression, specimens in which > 50% of the
tumor cells displayed strong staining were defined as
having ‘high-level total hnRNP K’ expression, and those
in which ≤ 50% of tumor cells showed strong stained
were defined as having ‘low-level total hnRNP K’ expres-
sion. For analysis of cytoplasmic hnRNP K, we used the
method described previously [5], a sample was defined
as ‘cytoplasmic positive’ in cases where >10% of the
tumor cells exhibited cytoplasmic staining and as ‘cyto-
plasmic negative’ where ≤10% of cells were stained. For
analysis of nuclear hnRNP K expression, specimens in
which >50% of tumor cells displayed strong staining
were defined as ‘high level of nuclear hnRNP K’ and
those where ≤50% of tumor cells stained strongly were
defined as ‘low level of nuclear hnRNP K.’ For analysis
of MMP-12 expression, specimens in which > 20% of
tumor cells displayed positive staining were defined as
having ‘high-level’ MMP-12 expression, and those in
which ≤ 20% tumor cells displayed positive staining were
defined as having ‘low-level’ MMP-12 expression. MMP-
12- and hnRNP K-positive tumor cells in representative
microscopic fields were scored independently by two ex-
perienced pathologists.
Western blotting
Whole cell lysates were prepared by incubating cells in
NP40 lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 1% Igepal CA-630 and protease inhibitors [4.76 μg/
ml leupeptin, 3.25 μg/ml aprotinin, 0.69 μg/ml pepstatin
and 1 mM phenylmethylsulfonyl fluoride]) on ice for
30 min. The lysates were then centrifuged at 12,000 × g at
4°C for 10 min to pellet cell debris, and the supernatant
was collected. In addition, the expression of MMP12 pro-
tein in the serum-free medium of NPC cells was measured
by Western blotting. Conditioned media were collected
and concentrated 20-fold using Amicon Ultra-4 centrifu-
gal filters (Millipore, Carrigtwohill Co., Cork, Ireland)
according to the manufacturer’s protocol. Protein concen-
tration was determined using the Bradford reagent. Equal
amounts of protein were resolved by electrophoresis on
SDS-polyacrylamide gels, and the resolved proteins were
transferred to nitrocellulose membranes. The membranes
were blocked in 0.1% TBS-Tween 20 (TBST) with 5%
non-fat dry milk for 1 h, and then incubated overnight
with anti-hnRNP K (1:1000), anti-MMP12 (1:500), anti-
PGK1(1:1000) (all from Santa Cruz Biotechnology, Santa
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NJ). The membranes were then incubated with secondary
antibodies coupled to horseradish peroxidase (1:5000),
and the results were visualized using an enhanced chemi-
luminescence system (Amersham Pharmacia Biotech, AB,
Uppsala, Sweden).
Zymography
NPC cells treated with hnRNP K-targeting siRNA were
cultured in serum-free medium for 48 h, and the condi-
tioned medium was harvested and concentrated 20-fold
using an Amicon Ultra-4 centrifugal filter (Millipore). The
protein concentration was quantified using the Bradford
reagent and protein was mixed with non-reducing sample
buffer. The protein mixture was heated at 37°C for 30 min
and separated by electrophoresis on an SDS-polyacryl-
amide gel containing 1 mg/ml α-casein. The gel was
washed twice with 2.5% Triton X-100 for 30 min at room
temperature (RT), and incubated in developing buffer
(50 mM Tris–HCl, pH 7.6, 15 mM NaCl, 10 mM CaCl2
and 0.02% NaN3) for 15 min at RT with gentle agitation.
The gel was then transferred to fresh developing buffer
and incubated at 37°C for 48 h, and then incubated in fix-
ing buffer for 15 min at RT with gentle agitation. The gel
was stained with 0.125% Coomassie blue at RT for 1 hr
and destained with fixing buffer; the solution was changed
every 15 min until caseinolytic bands were visible. The
caseinolytic band found at 54 kDa was subjected to zymo-
graphic measurement of MMP12 activity.
Plasmid construction
The promoter sequences of human MMP12 were ob-
tained from the UCSC genome browser. Using human
genomic DNA isolated from normal peripheral blood
mononuclear cells (PBMCs) as the template, we ob-
tained the MMP12 promoter −2000 (−2000 to +97) frag-
ment by PCR using the following primers: forward, 5'-
TCCCC CGGGA CATAG AAAAA TTATC TAGTC
CTACG TGTA-3' and reverse, 5'-CCGCT CGAGT
GTAAA CTTCT AAACG GATCA ATTCA GTTT-3'
(including SmaI and XhoI sites, respectively). The result-
ing PCR product was ligated into the SmaI and XhoI
sites of the pGL3-basic vector (Promega, Madison, WI).
To generate 5' serial deletions of the MMP 12 promoter,
fragments −1500 (−1500 to +97), −999 (−999 to +97),
−499 (−499 to +97), −399 (−399 to +97), −299 (−299 to
+97), −199 (−199 to +97), −99 (−99 to +97), −42 (−42 to
+97), −32 (−32 to +97) or +2 (+2 to +97) were amplified
from pGL3-MMP12 -2000 and ligated into the SmaI/
XhoI-treated pGL3-basic vector.
Luciferase assay
NPC-TW02 cells in 24-well plates were co-transfected
with 0.4 ng of pRL-TK (Promega) and 0.8 μg of pGL3-basic vector with or without MMP12 promoter frag-
ments, using Lipofectamine (Invitrogen) according to
the manufacturer’s instructions. After 24 hours, Firefly
and Renilla luciferase activities were measured using the
Dual-Glo Luciferase Assay System (Promega) according
to the manufacturer's instructions. Firefly luciferase ac-
tivities were normalized to Renilla activities. Each bar
represents an average of at least three independent ex-
periments, and the error bars show standard deviations
calculated using Microsoft Office Excel.
DNA pull-down assay
Probes corresponding to the potential binding elements
within the MMP12 promoter were generated by PCR
using the appropriate biotinylated primers, as follows:
−42/+97 (−42 to +97) forward, 5'-GGGAT GATAT
CAACT ATGAG TCACT CATAG G-3' and reverse, 5'-
TGTAA ACTTC TAAAC GGATC AATTC AG-3'; and
+2/+97 (+2 to +97) forward, 5'-AGAAC CCGGA CTAAG
GGC-3' and reverse, 5'-TGTAA ACTTC TAAAC GGATC
AATTC AG-3'. The biotinylated probes were conjugated
with M-280 Streptavidin Dynabeads (Invitrogen) in bind-
ing buffer (10 mM Tris–HCl, pH 7.5, 50 mM KCl, 1 mM
MgCl2, 1 mM EDTA, pH 8.0, 1 mM Na3VO4, 5 mM DTT,
5% glycerol, 0.3% NP-40) for 40 min at room temperature.
NPC-TW02 cells were extracted using the Compartmen-
tal Protein Extraction Reagent (Millipore), and nuclear
fractions (50 μg) were incubated with unconjugated Dyna-
beads in the presence of 25 μg/ml poly (dI:dC) for 20 min
at RT. The unbound fraction was incubated with 250 μg
of Dynabeads bound to 50 pmol of immobilized probe for
1 h at RT. The Dynabead-bound complexes were collected
using a Dynal MPC-S magnetic particle concentrator
(Dynal Biotech, Oslo, Norway) and washed with binding
buffer. The DNA-bound proteins were eluted in SDS sam-
ple buffer and assayed by Western blotting.
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed using a Magna ChIP™ Kit
(Millipore) according to the manufacturer’s protocol,
with modifications. Briefly, NPC-TW02 cells (1×107)
were cross-linked by treatment with 1% formaldehyde
for 10 min on ice, and the reactions were quenched with
glycine (0.125 M) for 10 min on ice. Fixed cells were
washed twice with ice-cold PBS and lysed for 15 min on
ice with the provided cell lysis buffer and protease inhib-
itors. The samples were then centrifuged at 800 x g for
5 min at 4°C, the supernatants were removed, and the
pellets were resuspend with the provided nuclear lysis
buffer and protease inhibitors. Chromatin was sheared
by sonication (eight times for 10 seconds each at 30%
output) on ice and centrifuged at 10,000 × g for 10 min
at 4°C. The supernatant was collected and diluted 10-
fold with ChIP dilution buffer (0.01% SDS, 1.1% Triton
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167 mM NaCl) containing protease inhibitors. The di-
luted samples were incubated overnight at 4°C with 4 μg
of an anti-hnRNP K antibody (Invitrogen) and magnetic
protein A/G beads (Millipore). Mouse IgG (Millipore)
was used as a control antibody. The immunocomplexes
were collected using a Dynal MPC-S magnetic particle
concentrator (Dynal Biotech) and washed once each in
low-salt buffer, high-salt buffer, LiCl buffer, and Tris-
EDTA buffer. The samples were resuspended in ChIP
elution buffer (200 mM NaCl, 1% SDS, 20 mM Tris–
HCl, pH 7.4) containing 100 μg/ml proteinase K, incu-
bated for 2 h at 62°C, and then incubated for 10 min at
95°C. The DNA fragments were further purified using a
QIAquick PCR Purification Kit (QIAGEN, Hilden,
Germany), and quantitative PCR was performed using
primers against the potential hnRNP K-binding elements
in the MMP12 promoter.
Lentiviral production and transduction
The negative control shRNA (lacZ) and two shRNAs
targeting different sequences of human MMP12
(KD1, clone ID TRCN0000050209; and KD2, clone ID
TRCN0000372998) in the pLKO.1-puro vector backbone
were purchased from the National RNAi Core Facility of
Academia Sinica (Taipei, Taiwan). For lentiviral produc-
tion, 293 T cells were seeded at 4 × 105/well in 6 well-
plates and transfected with 1.8 μg pCMV-Δ8.91, 0.2 μg
pMD.G and 2 μg lentiviral vector. Six hours after transfec-
tion, the culture medium was change to DMEM supple-
mented with 1% FCS. Supernatants were collected at 24
and 48 h after transfection, pooled, filtered through a
0.22-μm filter, and frozen at −80°C until use. For lentiviral
transduction, NPC-TW02 cells were seeded at 2 × 105/well
in 6-well plates and infected with lentivirus in the presence
of 8 μg/mL of polybrene. The transduced cells were se-
lected with 1 μg/ml puromycin for 2–3 weeks.
Cell proliferation assay
Equal numbers of MMP12-knockdown cell clones were
dispensed to 6-well plates, and total cell numbers were
counted on days 1, 2, 3 and 4 after plating. The results
are presented as the mean ± SD from four independent
experiments.
Cell migration and invasion assays
The migration and invasion of NPC cells were evaluated
using Transwell inserts (Corning Inc., Corning, NY,
USA) and Biocoat Matrigel invasion chambers (BD Bio-
sciences, Bedford, MA), respectively. For cell migration
assays, the cells were washed twice with serum-free
medium and resuspended in serum-free medium, and
1.8 × 105 cells in 0.1 ml were added to the upper cham-
ber of the apparatus. The lower chamber contained0.6 ml medium with 10% FBS. For cell invasion assays,
the same procedures were used, except that 2.5 × 105
cells were resuspended in 0.5 ml of serum-free medium,
and added to the upper chamber of the apparatus, while
the lower chamber contained 0.75 ml medium with 10%
FBS. After 24 h at 37°C, the migrated and invading cells
were fixed and stained for 20 min with 0.25% crystal vio-
let, 10% formaldehyde and 80% methanol, and the filters
were washed five times with ddH2O to remove non-
adherent cells. Ten to fifteen random fields (× 100 mag-
nification) were captured for each membrane. The mi-
grated or invading cells were counted and averages were
calculated; results were obtained from three independent
experiments. The relative fold-change in the number of
migrated or invasive cells is shown, with the results from
control cells given as 1.0. The effect of MMP12-specific
inhibitor PF-356231 (Enzo Life Science, Farmingdale,
NY) [41,42] on the migration of NPC cells was deter-
mined after culturing for 24 h in the presence of indi-
cated concentrations of inhibitor or DMSO (as vehicle
control). The invasive activities of NPC cells were deter-
mined after 24 h (NPC-TW02) or 36 h (NPC-HK1) of
treatment with inhibitor.
Statistical analysis
All statistical analyses were performed using the SPSS
13.0 statistical software package. The relationship be-
tween MMP12 expression and hnRNP K expression was
evaluated using the Pearson Chi-Square test. In vitro
data were analyzed with the Student’s t test. Differences
were considered significant at a level of P < 0.05.
Results
Systematic analysis of hnRNP K-regulated MMPs genes
We previously showed that hnRNP K contributes to the
metastasis of NPC cells in part by regulating down-
stream genes [7]. Since the MMP family proteins are
well known to be involved in tumor metastasis, we
tested if they could be regulated through hnRNP K. We
used Affymetrix cDNA microarrays to compare the ex-
pression profiles of MMP family genes in NPC-TW02
cells transiently transfected with hnRNP K-targeting
siRNA versus those transfected with negative control
siRNA, and in NPC tissue samples and adjacent normal
tissues. The 7 out of 23 MMP genes showed reduced ex-
pression (1.5-fold decrease) in hnRNP K-knockdown
cells (Additional file 2: Table S2), while 11 out of 23 were
elevated (1.5-fold increase) in NPC tissues (Additional
file 3: Table S3). Among these differentially expressed
genes, MMP1, MMP12, MMP13 and MMP28 were con-
sistently reduced in hnRNP K-knockdown cells (Figure 1A)
but elevated in tumor cells (Figure 1C). We further con-
firmed our microarray results using quantitative RT-PCR,
and found that the mRNA levels of MMP1, MMP12,
Figure 1 Identification of hnRNP K-targeted MMPs. (A) Affymetrix cDNA microarrays were used to examine the gene expression levels of
MMP1, MMP12, MMP13 and MMP28 in hnRNP K-knockdown versus control siRNA-transfected NPC-TW02 cells. (B) Verification of hnRNP K-regulated
MMP gene expression in NPC cells. NPC-TW02 cells were transfected with either hnRNP K-targeting (K) or control (C) siRNA. Cells were harvested post-
transfection 48 h to detect the MMPs mRNA expression levels by quantitative RT-PCR analyses. All data are presented as the mean ± SD from three
experiments. *P < 0.05. (C) Affymetrix cDNA microarrays were used to examine the gene expression levels of MMP1, MMP12, MMP13 and MMP28 in
NPC tumor versus adjacent normal tissues. (D) Quantitative RT-PCR analyses of MMP gene expression in nine matched-pairs of NPC tumor and
adjacent normal tissues.
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0.28-, 0.46- and 0.09-fold, respectively; P < 0.05) in hnRNP
K-knockdown cells compared with control siRNA-treated
NPC-TW02 cells (Figure 1B). On the other hand, the
mRNA levels of MMP1 and MMP12 were significantly el-
evated (14.2- and 56.3-fold, respectively; P < 0.05) in nine
matched-pairs of NPC tumor and adjacent normal tissues.
NPC tumor samples compared with adjacent normal tis-
sues, whereas the mRNA levels of MMP13 and MMP28
were not significantly different between the tumor and ad-
jacent normal tissues (Figure 1D). As MMP12 has not
previously been examined in the context of NPC, it was
chosen for further study.
Correlation of MMP12 and hnRNP K expression levels in
NPC tissues
The epithelial-stromal cell cross contamination is
known to be one of problems in the analysis of RNA/
protein expression from solid tumor. Therefore, 82 NPC
biopsy specimens were subjected to immunohistochemical
(IHC) analysis and the differential expression of MMP12
and hnRNP K between the tumor and normal epithelial
tissues were investigated. Patient characteristics and
clinical features are summarized in Table 1. In general,
our IHC data demonstrated that the NPC tumor cells
expressed higher levels of MMP12 compared to adja-
cent normal cells. As shown in Figure 2A-C, consecu-
tive tissue slides of the same set of specimens were used
to evaluate the protein expression levels of MMP12 and
hnRNP K. We further analyzed whether the expression
level of MMP12 correlated with the subcellular localization
Figure 2 Correlation of MMP12 and hnRNP K expression in NPC biopsy tissues. (A) Immunohistochemical staining of MMP12. A representative
NPC biopsy tissue sample containing adjacent nontumor (N) and tumor (T) cells stained with a specific MMP12 antibody is shown at 200x
magnification. (B and C) The N and T areas are shown at 400x magnification, respectively. (D-I) Consecutive NPC tissue sections were stained using
anti-hnRNP K and anti-MMP12 antibodies, and subjected to immunohistochemical assessment. Representative NPC tissue sections with high-level
expression of MMP12 (D and F) and total hnRNP K (E, NHi/C+; G, NHi/C−) and low-level expression of MMP12 (H) and hnRNP K (I, NLo/C−) are shown.
TotalHi, total hnRNP K high; TotalLo, total hnRNP K low; NHi, nuclear hnRNP K high; NLo, nuclear hnRNP K low; C+, cytoplasmic hnRNP K positive; C−,
cytoplasmic hnRNP K negative; scale bar in (A-C)= 100 μm, (D-I)= 50 μm.
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assessed the association between MMP12 expression (high
or low) and (1) the total hnRNP K expression (high or
low), or (2) the nuclear hnRNP K expression (high or
low), or (3) the cytoplasmic hnRNP K expression (positiveor negative). The statistical analysis was summarized in
Table 2. Statistical analyses revealed that high-level
MMP12 expression was significantly correlated with high-
level of total hnRNP K (P = 0.026; Table 2) and nuclear
hnRNP K (P = 0.042; Table 2), rather than cytoplasmic
Table 2 Correlation of hnRNP K and MMP12 expression
MMP12 expression P
High Low
Total hnRNP K 0.026*
High 32 15
Low 15 20
Nuclear hnRNP K 0.042*
High 25 10
Low 22 25
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http://www.biomedcentral.com/1471-2407/14/348hnRNP K (P = 0.168; Table 2). These results suggest that
nuclear hnRNP K was positively correlated with MMP12
in NPC tumor cells.
The expression and activity levels of MMP12 are
regulated by hnRNP K in NPC cells
To gain insight into the potential role of hnRNP K in
regulating MMP12 expression, we tested MMP12 ex-
pression in hnRNP K-knockdown and control cells of
two NPC cell lines (NPC-TW02 and -HK1). As shown
in Figure 3A, the level of MMP12 mRNA was reduced
significantly in hnRNP K siRNA-treated NPC cells com-
pared with control siRNA-treated cells. To assess
whether the effect of hnRNP K knockdown on MMP-12
mRNA was correlated with changes in the protein and/
or enzymatic levels, we performed Western blot andFigure 3 Suppression of hnRNP K expression downregulates the expr
were transfected with hnRNP K-targeting (K) or control (C) siRNA. Twenty-fo
medium for another 48 h. MMP12 mRNA levels were determined by quant
supernatant (Sup) and in the cell extract (CE), respectively, were examined
loading control for the secreted and the cytoplasmic proteins, respectively.
The supernatants from the NPC cells treated with either hnRNP K-targeting
to zymographic analysis. The protein levels of hnRNP K and actin in the cezymographic analyses. Conditioned media were obtained
from the above-described NPC cells and analyzed by im-
munoblotting and casein zymography. Western blot ana-
lysis and casein zymography showed that hnRNP K
knockdown significantly reduced the protein expression
and activity levels of MMP12 (54 kDa), respectively
(Figure 3A and B). Thus, hnRNP K knockdown inhibited
the mRNA expression, protein expression and enzymatic
activity of MMP12.
MMP12 is transcriptionally regulated by hnRNP K
We further clarified the mechanism(s) underlying the
hnRNP K-mediated regulation of MMP12 expression.
To discriminate between transcriptional activation and
post-transcriptional regulation, we analyzed the effect of
hnRNP K knockdown on MMP12 promoter activity and
mRNA stability. As shown in Figure 4A and B, NPC-
TW02 cells were treated with siRNA followed by trans-
fection of constructs containing 5' serial deletions of the
MMP12 promoter, and reporter activity was examined
24 h later. Our results revealed that knockdown of
hnRNP K significantly inhibited the activity of MMP12
promoter constructs containing the deletion from −2000
to −42 bp of the transcription start site. (P < 0.05). There
had no effect on MMP12 promoter (−32 to +97) while
cells treated with hnRNP K siRNA compared with con-
trol group (Figure 4B). Moreover, the MMP12 promoter
construct spanning −32 to +97 showed substantially less
activity compared with that spanning −42 to +97 (61.3% vs.
100%, respectively) (Figure 4B). These results collectively
suggest that the MMP12 promoter region covering −42
to −33 may be the potential hnRNP K response region.ession and activity of MMP12 in NPC. (A) NPC-TW02 and -HK1 cells
ur hours after transfection, cells were further cultured in serum-free
itative RT-PCR, and MMP12 and hnRNP K protein levels in the culture
by Western blotting. PGK1 and Actin protein levels were used as the
(B) The enzymatic activity of MMP12 was analyzed by zymography.
(K) or control (C) siRNA were collected after 48 h, and were subjected
ll extracts were analyzed by Western blotting.
Figure 4 Transcriptional regulation of MMP12 by hnRNP K. (A) Schematic diagrams of the utilized reporter constructs, which contained 5'
serial deletions of the MMP12 promoter. (B) NPC-TW02 cells were pretreated with control siRNA (C) or hnRNP K-targeting siRNA (K) for 24 h and
then transfected with pGL3-basic (pGL3) with or without 5' serial deletions of the promoter sequence of the MMP 12. Firefly and Renilla luciferase
activities were determined at 24 h post-transfection. *P < 0.05. (C) DNA pull-down assays were performed using nuclear extracts isolated from
NPC-TW02 cells and 5' biotin-labeled probes corresponding to the −42/+97 (−42 to +97) or +2/+97 (+2 to +97) regions of the MMP12 promoter.
The hnRNP K levels in the immunoprecipitates and 1% inputs were determined by Western blotting. (D) Chromatin immunoprecipitation was
carried out using nuclear extracts from NPC-TW02 cells and an antibody against hnRNP K, followed by quantitative PCR of a sequence within the
MMP12 promoter region (−95 to −20). Mouse IgG immunoprecipitation was done as a negative control. *P < 0.01.
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MMP12 promoter, we performed in vitro DNA pull-
down assays with probes spanning −42 to +97 and +2 to
+97 of the MMP12 promoter. As shown in Figure 4C,
hnRNP K specifically bound to probe (−42 to +97) but
not probe (+2 to +97), suggesting that the −42 to +1 re-
gion is indispensable for hnRNP K binding. To further
support our contention that hnRNP K can interact with
the endogenous MMP12 promoter, we performed a
chromatin-immunoprecipitation analysis. As shown in
Figure 4D, hnRNP K specifically immunoprecipitated
with the MMP12 promoter. Together, these results indi-
cated that the hnRNP K-responsive region is the se-
quence of −42 to −33 bp upstream of the MMP12
transcription start site.
In addition, we examined the effect of hnRNP K
knockdown on MMP12 mRNA stability. Treatment of
NPC-TW02 cells with actinomycin D to block de novo
RNA synthesis, and used quantitative RT-PCR to exam-
ine MMP12 mRNA levels at 2, 4, 8, 12 and 16 h post-
treatment. The half-life of the MMP12 mRNA was31.07 h in hnRNP K-knockdown cells and 38.17 h in con-
trol cells, which was not significantly different (Additional
file 4: Figure S1). Taken together, our findings indicate
that the hnRNP K-mediated changes in MMP12 gene
expression arise via promoter inhibition, not mRNA
destabilization.
MMP12 promotes NPC cell migration and invasion
To examine the biological function of MMP12 in NPC
cells, we established two MMP12-knockdown cell lines
using lentiviral transduction of two different MMP12-
targeting shRNA sequences. As shown in Figure 5A, the
MMP12 protein and mRNA levels were reduced in the
two MMP12-knockdown cell lines compared to control
cells transduced with a control shRNA targeting LacZ.
Importantly, cell migration (Figure 5B) and invasion
(Figure 5C) were significantly and dose-dependently re-
duced in the MMP12-knockdown cells compared to
controls (P < 0.05). However, the reduction of migration
and invasion in MMP12-knockdown cells were not due
to the difference in cell growth (Figure 5D) between
Figure 5 MMP12 promotes cell migration and invasion in NPC-TW02 cells. (A) MMP12 mRNA expression was detected in stable NPC-TW02
cells of MMP12-knockdown (KD1 and KD2) and control (LacZ) by quantitative RT-PCR, and MMP12 protein levels in the culture supernatant were
examined by Western blotting. PGK1 protein levels were used as the loading control for secreted proteins. Cell migration (B) and invasion (C)
assays were performed in stable NPC-TW02 cells of MMP12-knockdown (KD1 and KD2) and control (LacZ). Images were captured at 24 h under
12.5× magnification. The relative fold-change in the number of migrated cells is shown, with the results from control cells given as 1.0. All data
are presented as the mean ± SD from three independent experiments. *P < 0.05. (D) Cell growth in stable NPC-TW02 cells of MMP12-knockdown
(KD1 and KD2) and control (LacZ) was determined by counting the cell numbers for 4 days.
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tigated the effect of the treatment of PF-356231, a spe-
cific inhibitor of MMP12 on the migration and invasion
of NPC cells. As compared to untreated control, PF-
356231 treatment significantly and dose-dependently re-
duced the migration (Figure 6A) and invasion (Figure 6B)
in NPC-TW02 cells (P < 0.05). Similar results were ob-
served in NPC-HK1 cells (Figure 6C and D). Taken to-
gether, these results indicate that hnRNP K-mediated
MMP12 expression enhances the migration and invasion
of NPC cells. In addition, MMP12-mediated cell migration
and invasion can be inhibited by PF-356231 treatment.
Discussion
Overexpression of hnRNP K has been found in various
cancers and correlates with poor prognosis [3-5,43].
Here, we report a new function for hnRNP K-regulatingMMP12, which can induce cell migration and invasion
in NPC cells. We further show that the sequence −42
to −33 bp relative to the transcription start site of MMP12
is bound by hnRNP K, triggering the transcriptional acti-
vation of MMP12. Moreover, MMP12 promotes cell mi-
gration and invasion in NPC cells, and high-level
MMP12 expression was found to be correlated with in-
creased expression of hnRNP K in NPC patients. Col-
lectively, our findings show that hnRNP K binds the
MMP12 promoter, thereby inducing MMP12 expression
through transcriptional activation. This provides a
mechanistic explanation for the correlation of hnRNP K
with MMP12 and metastasis in NPC. Although we and
other groups have showed that an aberrant cytoplasmic
localization of hnRNP K was correlated with a poor
prognosis in many tumors including NPC [3,5,44], in
this study, we found that the nuclear but not the
Figure 6 MMP12-specific inhibitor, PF-356231, inhibits cell migration and invasion in NPC cells in a dose-dependent manner. Cell
migration and invasion assays were performed in NPC-TW02 (A and B) and in NPC-HK1 (C and D) cells, respectively, in the presence of different
concentration of MMP12 inhibitor PF-356231 (0, 25 and 50 nM). Images were captured under 12.5x magnification. The relative fold-change in the
number of migrated cells is shown, with the results from control cells given as 1.0. All data are presented as the mean ± SD from three independent
experiments. *P < 0.05.
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MMP12 expression level. Conceivably, only the nuclear
hnRNP K can transcriptionally regulate the MMP12
gene expression. On the contrary, TP, a hnRNP K target
gene, whose expression is upregulated through the in-
crease in its mRNA stability by the binding of cytoplas-
mic hnRNP K [11]. From these data, we can conclude
that hnRNP K has dual roles in different subcellular
localization. Whether nuclear or cytoplasmic hnRNP K
is responsible for regulating its downstream target genes,
it depends largely on the target gene itself.
HnRNP K overexpression has been correlated with
poor distant metastasis-free survival [5,45-47], suggest-
ing that hnRNP K can promote tumor metastasis. How-
ever, the underlying mechanism responsible for thispromotion of metastasis was previously unknown. In the
present study, our systematically analysis of the MMP
gene family revealed that MMP12 was induced by
hnRNP K and could promote cell migration and inva-
sion in NPC cells. Importantly, high-level MMP12 ex-
pression was correlated with increased expression of
hnRNP K in NPC patients, suggesting that MMP12 is at
least partially responsible for the hnRNP K-mediated
metastasis of NPC. Consistent with our hypothesis, ele-
vated expression of MMP12 was previously associated
with metastatic disease in non-small cell lung cancer
[27] and head and neck squamous cell carcinoma [25].
Activities of MMPs are linked to many metastasis-
associated events in cancer progression. Therefore,
MMPs may be the ideal targets for anti-cancer drug
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vasion was observed after MMP12 inhibitor PF-356231
treatment (Figure 6), implying that there are multiple
pathways, besides MMP12, may involve in promoting
cell motility in NPC. For instance, AP-1-mediated
MMP3 activation [48], NF-κB-mediated MMP9 activa-
tion [22], JNK/AP-1/DNMT/E-cadherin silencing [49]
and downregulation of microRNA-144- mediated PTEN
activation [50], these pathways have been reported to
promote migration ability in NPC. Therefore, hnRNP K-
mediated activation of MMP12 may partly contribute to
enhance NPC cell migration. In addition, recent work
has shown that forced overexpression of hnRNP K can
increase the invasive capacity of mouse fibroblasts
NIH3T3 by increasing MMP3 expression [45], although
the expression level of MMP3 was not changed in
hnRNP K-knockdown human NPC cells (Additional file 2:
Table S2). Taken together, the previous findings and our
present results indicate that hnRNP K may promote
tumor metastasis by modulating the ECM via MMP in-
duction. In addition, PF-356231 may be considered to
treat NPC metastasis with high MMP12 expression.
The MMPs are involved in many phases of cancer
progression, including tumor invasion, metastasis, and
angiogenesis [16,17]. In addition to MMP12 (present
study), MMP1 [51], MMP13 [52,53] and MMP28 [54]
have also been shown to promote invasion and metasta-
sis in various cancers. Importantly, hnRNP K can induce
the expression of MMP1, MMP12, MMP13 and MMP28
in NPC cells (Figure 1B) and the expression of MMP3 in
fibroblasts [45], suggesting that hnRNP K controls the
expression levels of various MMPs. In addition to its ef-
fects on tumor metastasis, hnRNP K can contribute to
tumor progression and malignancy through its antiapop-
totic function [7,11]. Thus, the results of the present and
previous studies collectively suggest that hnRNP K
should be considered a potential target for the future de-
velopment of new anticancer agents.
Previous studies have demonstrated that MMP2 and
MMP9 expression can be induced in EBV-infected NPC
cells [55]. Furthermore, it has been reported that the re-
sponse of NPC cells to EBV infection is mediated mainly
by the NF-κB and STAT3 signal cascades [56]. EBV in-
fection has been known to lead to NPC tumorigenesis.
And LMP1 is the most important viral oncoprotein that
alters many cellular gene expression e.g. MMP2 and
MMP9. We speculate that MMP induction initially re-
quired EBV infection and LMP1 expression, however,
once the cells become NPC tumor cells, the presence of
EBV or LMP1 is probably less important.
Although hnRNP K can regulate gene expression by
binding to DNA and RNA [6,57], we found that it in-
duces MMP12 mRNA expression by activating the
MMP12 promoter rather than stabilizing the MMP12mRNA (Additional file 4: Figure S1). Similar to the tran-
scriptional induction of MMP12 by AP-1 [29,30], NFκB
[29], β-catenin [58,59], YB-1 [60] and PPARα agonist
[61], we herein show that hnRNP K can induce MMP12
expression through its association with the sequence −42
to −33 bp upstream of the MMP12 transcription start site.
Previous studies showed that hnRNP K can regulate pro-
moter activity by interacting with DNA-bound transcrip-
tional activators [7,62]. The −42 to −33 bp region is close
to an AP-1-responsive element at −26 to −19 [30], sug-
gesting that future studies are warranted to examine the
potential interaction of hnRNP K and AP-1.Conclusions
We herein show that hnRNP K exerts a metastatic
function by inducing MMP12 via its binding to the −42
to −33 bp region of the MMP12 promoter, which controls
transcriptional activation. MMP12 is overexpressed in
NPC, and its expression is correlated with that of hnRNP
K in NPC patients. Moreover, NPC metastasis with high
MMP12 expression may be treated with MMP12-specific
inhibitor, PF-356231. Based on these novel findings, we
propose that hnRNP K and MMP12 should be considered
as potential targets for the development of new anticancer
agents.Additional files
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